Benefits of Peptides: What the Science Says
Unlocking the Evidence-Based Advantages of Peptides for Muscle Repair, Fat Loss, and Skin Health
Introduction
Peptides are short chains of amino acids that act as signaling molecules in the body, influencing processes such as tissue repair, metabolism, and skin regeneration. In recent years, both research peptides and licensed peptide-based medicines have gained attention for their potential to support muscle recovery, promote fat loss, and enhance skin health. This page reviews the latest scientific evidence for each benefit area, focusing on the products offered by thepeptidecompany.co.uk.
01 — Summary Table: Peptides and Their Evidence-Based Benefits
| Peptide | Primary Benefit | Evidence Level | UK Status |
|---|---|---|---|
| BPC-157 | Muscle & Tendon Healing | Robust preclinical; limited human data | Research only |
| Ipamorelin | Muscle Preservation & GH Release | Preclinical models | Research only |
| Semaglutide | Weight Loss & Cardiometabolic | Multiple Phase 3 RCTs, NICE approved | Prescription (Wegovy®) |
| Retatrutide | Accelerated Fat Loss | Phase 2 trials — up to 24.2% loss | Research only |
| Tesamorelin | Visceral Fat Reduction | RCTs in HIV lipodystrophy | Research only (UK) |
| GHK-Cu | Collagen & Skin Renewal | In vitro & ex-vivo studies | Research only |
| Collagen Peptides | Skin Hydration & Elasticity | Multiple meta-analyses (RCTs) | Food supplement |
02 — Muscle Repair and Recovery
BPC-157: The Healing Peptide
What is BPC-157?
BPC-157 is a synthetic peptide derived from a protein found in the stomach. It has gained attention for its regenerative effects on muscle, tendon, and ligament tissues.
Evidence-Based Benefits
A 2024 systematic review found that BPC-157 significantly promotes healing of musculoskeletal injuries — including fractures, tendon ruptures, and muscle injuries — in preclinical models. Mechanisms include upregulation of growth hormone receptors, angiogenesis, and reduction of inflammation.
In animal studies, BPC-157 reversed corticosteroid-impaired muscle healing and improved tendon-to-bone healing.
BPC-157 accelerated muscle healing, restored function, and reduced edema and contracture in rat models of muscle crush injury.
Ipamorelin: Growth Hormone Secretagogue
What is Ipamorelin?
Ipamorelin is a pentapeptide that selectively stimulates the release of growth hormone (GH), supporting muscle protein synthesis and tissue repair.
Evidence-Based Benefits
In animal models, ipamorelin counteracted glucocorticoid-induced muscle loss and increased muscle strength and bone formation.
Ipamorelin has high specificity for GH release, with minimal effect on other hormones, making it a promising candidate for muscle and tissue repair.
03 — Fat Loss and Metabolic Health
Semaglutide: Transforming Weight Management
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist, licensed in the UK as Wegovy® for weight management and Ozempic® for type 2 diabetes.
Evidence-Based Benefits
16% mean weight loss at 68 weeks with semaglutide 2.4 mg weekly, compared to 5.7% with placebo.
15.2% weight loss at 2 years, sustained over 104 weeks.
33.4% of users achieved ≥20% weight loss in meta-analysis findings.
20% reduction in major adverse cardiovascular events in adults with overweight/obesity and cardiovascular disease.
Retatrutide: The Next Generation
What is Retatrutide?
Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) currently in clinical trials for obesity.
Up to 24.2% mean weight loss at 48 weeks with 12 mg weekly; 86% of participants achieved ≥15% weight loss.
Retatrutide outperformed other GLP-1 agonists for achieving ≥15% weight loss. Weight loss was primarily from fat mass, with preservation of lean mass.
Tesamorelin: Targeting Visceral Fat
What is Tesamorelin?
Tesamorelin is a growth hormone-releasing hormone analogue, licensed for HIV-associated lipodystrophy.
~18% reduction in visceral adipose tissue (VAT) over 6 months in HIV patients. Improved triglycerides, adiponectin, liver enzymes, and muscle area in VAT responders. VAT reduction maintained for up to 52 weeks with continued use.
04 — Skin Health and Anti-Ageing
GHK-Cu (Blue Copper Peptide): Collagen and Skin Renewal
What is GHK-Cu?
GHK-Cu is a naturally occurring copper peptide with potent effects on skin regeneration and anti-ageing.
GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis, supporting dermal fibroblast function and tissue repair. In combination with hyaluronic acid, GHK-Cu upregulated collagen IV synthesis by 25.4-fold in cell models and 2.03-fold in ex-vivo skin.
Accelerates wound healing, improves skin elasticity, and reduces wrinkles and photodamage. Modulates metalloproteinase activity, promoting skin density and resilience.
Collagen Peptides: Hydration and Elasticity
What are Collagen Peptides?
Collagen peptides are hydrolysed forms of collagen, often used as dietary supplements to support skin health.
Oral collagen peptide supplementation significantly increased skin hydration and elasticity in 1,721 participants across 26 RCTs. Systematic Review (2024): Statistically significant increases in skin hydration (SMD 1.25) and elasticity (SMD 0.61) with a median dose of 4 g/day.
05 — Regulatory Disclaimer
Important Regulatory Notice
- Semaglutide is a licensed prescription medicine in the UK, regulated by the MHRA and NICE. Available only via prescription for approved indications.
- BPC-157, GHK-Cu, Ipamorelin, Tesamorelin, and Retatrutide are not licensed medicines in the UK. They are supplied strictly for laboratory research purposes and are not intended for human consumption or therapeutic use. No medical claims are made for these products.
06 — FAQs: Peptides in the UK
07 — References
- Pickart L, Margolina A. GHK-Cu may prevent oxidative stress in skin. Int J Mol Sci. 2018;19(7):1980. PubMed
- Park JR, et al. GHK-Cu and hyaluronic acid synergistically upregulate collagen IV synthesis. Skin Pharmacol Physiol. 2023;36(2):123-132.
- Choi FD, et al. Oral collagen supplementation: A systematic review. Int J Dermatol. 2023;62(2):e77-e89.
- de Miranda RB, et al. Effects of collagen supplementation on skin hydration. J Cosmet Dermatol. 2024.
- Wadden TA, et al. STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes. N Engl J Med. 2023;389:2221-2232.
- NICE Technology Appraisal [TA875]: Semaglutide for managing overweight and obesity.
- Jastreboff AM, et al. Retatrutide, a novel triple hormone receptor agonist for obesity. N Engl J Med. 2023;389:2241-2254.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2010;363(7):701-713.
- Vranes M, et al. The role of BPC-157 in musculoskeletal injury healing: A systematic review. Orthop J Sports Med. 2024.
- Hansen TK, et al. Ipamorelin counteracts glucocorticoid-induced muscle and bone loss in rats. J Bone Miner Res. 2001;16(11):2068-2075.
- MHRA. Guidance on the supply of unlicensed medicines. MHRA
- NHS. Semaglutide (Ozempic, Wegovy) for diabetes and weight loss. NHS
This page is for informational and research purposes only. No products are sold for human consumption unless specifically licensed by the MHRA/NICE. Always consult a healthcare professional for medical advice.